Med. praxi. 2011;8(3):123-125

Helicobacter pylori infection

MUDr.Tomislav Švestka, CSc.
IV. interní klinika, 1. LF UK a VFN, Praha

The last twenty years have seen as a period of major revolution in the medicine. Patogenesis of peptic ulcer disease has probably seen the

greatest changes both conceptually and in practice. There has been a explosion of information concerning Helicobacter pylori (Hp) and

ulcer disease. Eradication of Hp infection is useful in clinical cure of infected patients. Efficacious regimens generally include a several

combinations of antisecretory agent combined with two antimicrobials. Resistance can occur to the commonly used antibiotics but can

be usually overcome with an altered regimen. It is important for physicians to clearly understand when and how to test and to select

appropriate therapy for Hp infection.

Keywords: Helicobacter pylori, ulcer disease of stomack and duodenum, the Maastricht III Consensus Report 2006

Published: March 23, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Švestka T. Helicobacter pylori infection. Med. praxi. 2011;8(3):123-125.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active gastritis. Lancet 1983; 1: 1273-1275. Go to original source...
    2. Bizzozero G. Über die Schlauchförmigen Drüsen des Magendarmkanal und die Bezienhungen ihres Epithels zu dem Oberflächenepithel der Schleimhaut. Arch Microbiol Anat 1983; 42: 82-152. Go to original source...
    3. Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter Pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-368. Go to original source... Go to PubMed...
    4. Lehours P, Yilmaz O. Epidemiology of Helicobacter pylori infection. Helicobacter 2007; 12(Suppl 1): 1-3. Go to original source... Go to PubMed...
    5. Bureš J, Kopáčová M, Rejchrt S. Pokles prevalence infekce Helicobacter pylori v České republice. Čas Lék čes 2008; 147: 255-257.
    6. Kopáčová M, Bureš J, Voříšek V. Současné možnosti diagnostiky Helicobacter pylori. Vnitř lék 2000; 46: 341-346. Go to PubMed...
    7. Švestka T, Krechler T, Brůha R, Jablonská M. Problematika infekce Helicobacter pylori chorob žaludku a duodena. Čas Lék čes 2004; 143(11): 734-738.
    8. Suzuki H, Masaoka T, Nomura S, et al. Current consensus on the diagnosis and treatment of Hp-associated gastroduodena disease. Keio J Med 2003; 52(3): 163-171. Go to original source... Go to PubMed...
    9. Malfertheiner P, et al. Current concept in the management of Helicobacter pylori infection-The Maastricht II-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180. Go to original source... Go to PubMed...
    10. Malfertheiner P, et al. Current concept in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. GUT 2007; 56: 772-781. Go to original source... Go to PubMed...
    11. Fixa B., Vaňásek T. Léčba infekce Helicobacter pylori rezistentní na standardní léčbu. Současný stav a perspektivy. Čes a Slov Gastroent a Hepatol 2009; 63(2): 65-73.
    12. Kopáčová M, Bureš J. Sekvenční léčba Helicobacter pylori. Folia Gastroent Hepatol 2009; 7(2): 82-84.
    13. Švestka T, Krechler T, Brůha R, Jablonská M. Indikace k eradikaci a léčbě infekce Helicobacter pylori. Čas Lék čes 2004; 143(12): 850-854.
    14. Sánchez-Delgado J, Calvet X, Bujana L, et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical praktice. Am J Gastroenterol 2008; 103(9): 2220-2223. Go to original source... Go to PubMed...
    15. Tong JL, Ran ZH, Shen J, et al. Sequential therapy v. s. standart triple therapies for Helicobacter pylori infection: a metaanalysis. J Clin Pharm Ther 2009; 34(1): 41-53. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.